New publication on technology transfer
Our publication, Technology Transfer: A Collaborative Approach to Improve Global Health, summarizes the current landscape for technology transfers, the 10 factors that enable success, and how different stakeholders can work together to deliver on prerequisites.
Read More
Policy Perspectives from the Innovative Biopharmaceutical Industry
Together with the global health community the biopharmaceutical industry is committed to improving pandemic preparedness for the future.
Read More
COVID-19
IFPMA members commit to accelerate their effort to use their skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. Visit IFPMA COVID-19 Hub.
Read More
#TeamVaccines campaign
The world doesn’t just need COVID-19 vaccines. We need people around the world to feel confident in getting them, when it’s their turn. This campaign is an opportunity for all of us to help spread confidence and trust in the vaccines! Join #TeamVaccines now!
#TeamVaccines
Call to Action On Routine and Life-Course Immunization in the Context of the COVID-19 Pandemic
Life-course immunization can contribute to healthier, more productive, and longer lives, which enhances the sustainability of healthcare systems
Read More
The African Medicines Agency
AMA has the unique opportunity to become one of the most efficient and modern regulatory systems in the world.
Read More
AMR Action Fund
More than 20 leading pharmaceutical companies launched a ground-breaking collective venture - the AMR Action Fund - to bridge the current gap in funding for the development of new antibiotics
Read More
IFPMA Code of Practice eLearning
Our Code of Practice has evolved over time and it promotes a culture grounded on values, principles and decisions based on good judgement. You can take our new eLearning here!
Start training hereIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Ethics and Business Integrity
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Inventing Medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
Influenza vaccination during the COVID-19 pandemic
Read More
Why is flu vaccination so important during the COVID-19 pandemic?
IFPMA_HPP_Why is flu vaccination so important during the COVID-19 pandemic_Infographic
Read More
The Nagoya Protocol and Pathogen Sharing (Video)
Read More
As COVID-19 vaccine output estimated to reach over 12 billion by year end and 24 billion by mid-2022, innovative vaccine manufacturers renew commitment to support G20 efforts to address remaining barriers to equitable access
This month, COVID-19 vaccine manufacturing output will pass the 9.3 billion dose mark. The biopharmaceutical industry renews its May commitment to the G20 to collaborate with governments to support effective solutions to urgently address vaccine equity. At current production rates, swiftly rolling out vaccines to those who still need them...
Read More
Greg Perry - IFPMA Moderated Panels @Pre-ICDRA 2018
Read More
IFPMA EFPIA PhRMA BIO ABPI Statement - Global COVID-19 Summit: Ending the Pandemic and Building Back Better
Innovative biopharmaceutical companies are at the forefront of the response to the pandemic; not least by developing and manufacturing COVID-19 vaccines in record time. Our industry joins today’s global summit to demonstrate our commitment towards working with governments and global health partners to align on a common vision to expand...
Read More
Join IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MOREOur Blog
How far we have come and how far we have yet to go
Against the backdrop of increasing concerns around Omicron, last week we convened a media briefing on the biopharmaceutical industry’s efforts over the past year since the first COVID-19 vaccine was administered. This was a unique opportunity to share insights from the Biotechnology Innovation Organization (BIO) and the Developing Countries Vaccine Manufacturers’ Network (DCVMN) and the IFPMA. These three trade groups represent most of the major players in...
Read More
Leveling the playing field for women in science and technology innovation in Africa
Innovation is crucial to identifying solutions to Africa’s healthcare needs. However, without the participation of women in the fields of Science, Technology, Engineering, and Mathematics (STEM), Africa and the world is bound to miss their invaluable perspectives and critical contributions. Women account for 30 percent of Sub-Saharan Africa's researchers and innovators and face limited access to funding and skills gaps that are key to business...
Read More
It's time to put an end to pathogen protectionism
This op-ed was originally published for Swissinfo on 16 December 2021. Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations, calls for unrestricted access to pathogen sharing to help the world prepare for new variants and future pandemics. Before the Covid-19 pandemic, only experts knew what “genome sequencing” meant. This changed when scientists in China swiftly shared the SARS CoV-2 genome...
Read MoreLatest Tweets
